News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

CULVER CITY, Calif.--(BUSINESS WIRE)--Aug. 16, 2021-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, appointed Patrick Soon-Shiong, M.D., to the newly created role of Global Chief Scientific and Medical Officer, effective as of August 11, 2021. In this additional role, Dr. Soon-Shiong will oversee the company’s global research and development programs and pipeline investments in support of its ambitious growth plans, which include bringing advanced technology to a broad global marketplace. “As both the founder of ImmunityBio and a visionary biotech innovator, Patrick’s expertise has always been an invaluable asset to the organization,” said Richard Adcock, President and CEO of ImmunityBio. “We are grateful for his leadership and commitment to drive the scientific agenda of our business forward. His unwavering focus on advancing potential breakthrough therapies for cancer and infectious disease has already improved the quality of life for thousands of patients.” “My entire life’s work has been to discover and bring to market better treatments for cancer and other difficult-to-treat diseases, and thanks to incredible innovations over the last few years, we’re closer than ever to that goal,” said Dr. Soon-Shiong. “Our growing knowledge of the immune system will serve as the foundation for the research priorities we’re setting at ImmunityBio. These priorities will guide our ongoing quest for life-saving and life-extending therapeutics, including a commitment to ensure they are available to people in underserved nations in Africa and elsewhere. That’s my goal and the goal of everyone on our highly experienced research, clinical development, and medical teams.”

ImmunityBio Appoints Dr. Patrick Soon-Shiong to Global Chief Scientific and Medical Officer; Newly Created Role Will Lead Company’s Scientific Strategy and Global Expansion Dr. Soon-Shiong’s priority will be to continue to align scientific and medical goals that are focused on the delivery of cutting-edge therapeutics for patients. The role connects Dr. Soon-Shiong’s long-time expertise, track record and innovative thinking as a clinician scientist directly with the company’s talented research/discovery, clinical development, and medical teams. The new position is in addition to Dr. Soon-Shiong’s existing role as the company’s Executive Chairman of the Board.

ImmunityBio, Inc. @ImmunityBio vor 23 Std. : This broad-ranging interview with IB Chairman @DrPatSoonShiong covers our COVID-19 universal boost trials in South Africa, progress on our war against cancer, and Kevin Merida's exciting plans for the LA Times: https://youtu.be/-h3B0YvwBmk $IBRX @Tuliodna @meridak

110 Millionen Dollar für Zelltherapie-Krebsspezialist T-Knife Das Berliner Start-up will mit der neuen Finanzierung die innovative Therapie mit T-Zellen vorantreiben. Bald sollen klinische Studien für Produkte starten. https://www.google.com/amp/s/amp2.handelsblatt.com/unternehmen/industrie/biotechnologie-110-millionen-dollar-fuer-zelltherapie-krebsspezialist-t-knife/27475202.html

If South African born billionaire Doctor Patrick Soon-Shiong's upcoming vaccine trial goes well, there could be 15 million COVID-19 vaccines produced in the country within 12 months. https://youtu.be/-h3B0YvwBmk

Aus dieser Studie dürfen wir in den nächsten Wochen und Monaten Ergebnisse erwarten, denn der primäre Abschluss ist für Juni angesetzt und der Abschluss der kompletten Studie mit August 2021. https://clinicaltrials.gov/ct2/show/NCT03228667?term=immunitybio&draw=2&rank=3

ImmunityBio, Inc. @ImmunityBio 30. Juli "The success of the COVID-19 vaccines has demonstrated the value and effectiveness of next-generation platforms, which have the potential to entirely change our approach to global disease prevention. Click here to learn more: https://bloom.bg/3fdKNsu #IBRX #Vaccine #Ad5 #COVID19"

ImmunityBio, Inc. @ImmunityBio 29. Juli "In clinical trials, the NANT Cancer Vaccine approach has been shown to induce complete remission across multiple tumor types in patients who previously progressed on standard-of care therapy. #ImmunityBio #NANTCancerVaccine $IBRX"

Billionaire Soon-Shiong Sees His Shot as a Universal Booster https://www.bloomberg.com/news/articles/2021-07-27/billionaire-soon-shiong-sees-his-covid-shot-as-universal-booster

ImmunityBio’s Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. Patent https://ir.immunitybio.com/news-releases/news-release-details/immunitybios-novel-immunotherapy-nant-cancer-vaccine-currently?field_nir_news_date_value[min]=

Soon-Shiong has been the biggest loser in the selloff. He owns roughly 314 million shares, or 82% of ImmunityBio’s common shares. His stake on March 10 was worth $12.2 billion. But by July 20, his position had collapsed to $3.58 billion, wiping out nearly $8.6 billion in value — on paper at least.